TY - JOUR T1 - Microparticles in COVID-19 as a link between lung injury extension and thrombosis JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00954-2020 SP - 00954-2020 AU - Olivier Morel AU - Benjamin Marchandot AU - Laurence Jesel AU - Laurent Sattler AU - Antonin Trimaille AU - Anais Curtiaud AU - Mickael Ohana AU - Samira Fafi-Kremer AU - Valerie Schini-Kerth AU - Lelia Grunebaum AU - Jean-Marie Freyssinet Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/04/15/23120541.00954-2020.abstract N2 - Among the distinctive features of COVID-19, numerous reports have stressed the importance of vascular damages associated with coagulopathy onset [1]. Histologic analysis of pulmonary vessels in patients with Covid-19 revealed severe endothelial injury associated with intracellular SARS-CoV-2 virus and disrupted endothelial cell membranes together with widespread thrombosis and occlusion of alveolar capillaries. Microparticles (MPs) shed by apoptotic/stimulated cells of various cellular lineages including platelets, leukocytes, macrophages, lung endothelium or endothelial cells are reliable markers of vascular damage [2] released upon pro-inflammatory conditions and behave as active participants in the early steps of clot formation [3]. Circulating MPs promote pro-coagulant responses due to the exposure of tissue factor, the physiological activator of the coagulation cascade, and of negatively-charged phospholipids such as phosphatidylserine required for the assembly of the tenase and prothrombinase coagulation complexes ultimately leading to thrombin generation, through which they can precisely be quantified [4].FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Olivier Morel: Dr. has nothing to disclose.Conflict of interest: Dr. Marchandot has nothing to disclose.Conflict of interest: Dr. Jesel has nothing to disclose.Conflict of interest: Dr. Sattler has nothing to disclose.Conflict of interest: Dr. Trimaille has nothing to disclose.Conflict of interest: Dr. Curtiaud has nothing to disclose.Conflict of interest: Dr. Ohana has nothing to disclose.Conflict of interest: Dr. Fafi-Kremer has nothing to disclose.Conflict of interest: Dr. Schini-Kerth has nothing to disclose.Conflict of interest: Dr. Grunebaum has nothing to disclose.Conflict of interest: Dr. Freyssinet reports other from HYPHEN BioMed, during the conduct of the study; In addition, Dr. Freyssinet has a patent WO1996003655A1 with royalties paid to HYPHEN BioMed and Patent WO1996003655A1 expired several years ago, in 2013-2014 as far as it can be remembered, when giving up paying for yearly fees no longer covered by royalties from HYPHEN BioMed for their Zymuphen MP-activity kits. For instance, patent fee for 2012 was 1902.83 EUR for France and Germany only, not including Japan and US rights. Last royalties, over 36 months (3 years) amounted to 5153 EUR, submitted to 16% taxes paid to the French tax system. ER -